Marquette General Cancer Center

 

Breast

 

Study Name - NSABP B46-1

 

Study Description -

A Phase III Clinical Trial Comparing the Combination of TC
Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer.

 

IRB Open Date - 01/13/2010

 

Consent

 

Data Privacy Statement for Research Studies

 

 

 

 

 

Study Name -NSABP PROTOCOL B-43

 

Study Description -
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with
Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive
Ductal Carcinoma In Situ Resected by Lumpectomy

 

IRB Open Date - 06-11-2008

 

Consent Pre Entry

 

Consent

 

Data Privacy Statement for Research Studies

 

 

 

Study Name - NSABP B44 Beth

 

Study Description -
NSABP B44 BETH - A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab CIRG (TRIO) 011/NSABP B44-1/B020906.

 

IRB Open Date - 04-09-2008

 

Consent- form - Her2 testing

 

Consent - NSABP B44 Beth

 

Data Privacy Statement for Research Studies

 

 

Study Name - TAILOR X

 

Study Description -
Program for the Assessment of Clinical Cancer Tests (PACCT-1) Trial Assigning IndividuaLized Options for Treatment (TAILORx)

 

IRB Open Date - 08-08-2007

 

Consent-Form

 

Data Privacy Statement for Research Studies

 

 

 

 

 

 

<< Back